Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDamora Therapeutics, Inc.

Damora Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
24.66 USD 0.96 ( 4.05%)
Last update at 2026-11-09T15:42:00Z
VOLUME
60777
Market Cap
1527.95M

Momentum Score

…

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
23.34
Low
24.68
High
52 Week Price Range
2.77
Low
38.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Damora Therapeutics, Inc. is a Nasdaq-listed biotechnology company with limited public disclosures indicating it focuses on therapeutic research rather than commercial operations. Its long-term outlook may depend on advancement of its development programs, positive clinical data and the ability to form strategic collaborations that could support pipeline progression. The company may appeal to investors seeking early-stage exposure to potential clinical or licensing upside tied to research milestones.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
23.70
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-99.74%
Net Debt
-257.56M
ROCE
-87.69%
Diluted EPS TTM
-0.23

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -209.79M -21.40M -38.35M -61.62M -51.75M
Net income -209.84M -21.44M -38.35M -61.62M -51.75M
Selling general administrative 9.69M 10.50M 12.69M 13.00M 13.74M
Gross profit -0.03M -0.18M -0.83M -0.49M -0.44M
Reconciled depreciation 0.03M 0.18M 0.83M 0.49M 0.44M
Ebit -210.87M -16.90M -36.46M -61.21M -52.23M
Ebitda -210.84M -16.72M -35.63M -60.72M -51.79M
Depreciation and amortization 0.03M 0.18M 0.83M 0.49M 0.44M
Operating income -210.87M -16.90M -36.46M -61.21M -52.23M
Other operating expenses 210.87M 16.90M 36.46M 61.21M 52.23M
Tax provision 0.05M 0.04M 0.00M - -
Interest income 1.17M 0.84M 1.69M 0.72M 0.16M
Net interest income 1.17M 0.84M 1.69M 0.72M 0.16M
Income tax expense 0.05M 0.04M - - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 210.87M 16.72M 35.63M 60.72M 51.79M
Cost of revenue 0.03M 0.18M 0.83M 0.49M 0.44M
Total other income expense net 1.08M -4.50M -1.89M -0.42M 0.47M
Net income from continuing ops -209.84M -21.44M -38.35M -61.62M -51.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 260.53M 17.13M 38.23M 73.19M 122.22M
Other current assets 1.90M 1.78M 1.91M 2.31M 7.63M
Total liab 20.15M 2.66M 5.90M 11.44M 4.99M
Total stockholder equity 240.38M 14.47M 32.33M 61.75M 117.22M
Other current liab 19.61M 0.81M 3.94M 7.28M 2.61M
Capital stock 416.25M 1.36M 0.00M 0.00M 0.00M
Retained earnings -487.36M -277.52M -256.08M -217.74M -156.11M
Cash 257.62M 14.18M 21.46M 32.79M 62.56M
Total current liabilities 20.07M 1.20M 5.83M 11.11M 4.54M
Net debt -257.56M -12.74M -21.22M -31.98M -61.72M
Short term debt 0.01M 0.01M 0.18M 0.48M 0.40M
Short long term debt total 0.07M 1.43M 0.25M 0.80M 0.85M
Other stockholder equity 310.69M 291.90M 288.04M 279.73M 273.65M
Total current assets 260.42M 16.84M 36.77M 63.91M 110.10M
Long term investments - - 0.00M 5.83M 9.05M
Short term investments - 0.00M 11.69M 27.44M 37.63M
Net receivables 0.90M 0.88M 1.72M 1.38M 2.28M
Accounts payable 0.44M 0.38M 1.70M 3.35M 1.53M
Accumulated other comprehensive income 0.80M 0.10M 0.38M -0.24M -0.32M
Non currrent assets other - 0.16M 1.13M 2.28M 2.03M
Non current assets total 0.10M 0.29M 1.45M 9.28M 12.11M
Capital lease obligations 0.07M 0.07M 0.25M 0.80M 0.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 11.65M 22.25M 12.58M -47.83M
Total cashflows from investing activities -17.37M 11.65M 22.33M 12.38M -48.05M
Total cash from financing activities 266.84M 0.00M 2.88M 0.51M 0.00M
Net income -209.84M -21.44M -38.35M -61.62M -51.75M
Change in cash 243.45M -7.29M -11.32M -29.78M -101.02M
Begin period cash flow 14.18M 21.46M 32.79M 62.56M 163.58M
End period cash flow 257.62M 14.18M 21.46M 32.79M 62.56M
Total cash from operating activities -6.73M -18.62M -36.91M -42.93M -52.31M
Issuance of capital stock 266.81M 0.00M 2.88M 0.51M 0.00M
Depreciation 0.03M 0.18M 0.83M 0.49M 0.44M
Other cashflows from financing activities 266.84M - - - -
Capital expenditures 0.00M 0.00M 0.00M 0.20M 0.22M
Change in working capital 18.36M -2.67M -4.37M 11.94M -6.62M
Stock based compensation 1.00M 3.24M 5.43M 5.57M 4.48M
Other non cash items 183.72M 5.30M 4.98M 6.26M 5.63M
Free cash flow -6.73M -18.62M -36.91M -43.13M -52.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DMRA
Damora Therapeutics, Inc.		 0.96
4.05%		 24.66 - - - 4.54 0.46
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Building 23, Waltham, MA, United States, 02453

781 281 9020

https://www.damoratx.com

7

Name Title Year Born
Ms. Lori C. Firmani Chief Financial Officer 1974
Mr. Garrett Winslow Esq. Senior VP, General Counsel & Corporate Secretary 1980
Ms. Jennifer A. Jarrett M.B.A. CEO, President & Director 1971
Mr. Ulf J. Nilsson Ph.D. Co-Founder NA
Dr. Hakon Leffler M.D., Ph.D. Co-Founder NA
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder NA
Mr. Sherwin Sattarzadeh Chief Operating Officer NA
Dr. Becker Hewes M.D. Chief Medical Officer 1967
Mr. Garrett Winslow Esq. Senior VP, General Counsel & Corporate Secretary 1979
Mr. Brian Burkavage CPA Senior VP of Finance, Principal Financial & Accounting Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…